spacer
home > ebr > current issue
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2015

   
Text
PDF
Editor’s Letter

Deborah O’Neil
contemplates the need for strategies to combat infectious diseases, regardless of the affected region, as well as looking at a number of this edition’s features.
 
view
download pdf
bullet
BioResearch and Innovation
In Vitro Testing

Super Models


Kirkstall’s J Malcolm Wilkinson
and Kelly S Davidge examine in vitro alternatives to animal testing. Although generally restricted to niche uses in academia, these more representative and complex models could one day be utilised in commercial drug development.
 
view
download pdf
bullet
Discovery Technology
Substance Identification

Compound X


Extractable compounds can be hard to identify, with investigations often proving time-consuming and expensive. Silvia Scotti, Simone Carrara and Marco Giulio Rozio at Eurofins BioPharma Product Testing Italy consider the need for a more systematic approach and extractables database.
 
view
download pdf
Drug Repositioning

Same Drug: New Purpose


Repositioning has been used to speed up productivity issues in current drug development and address unmet patient needs. José Manuel Mas and Judith Farrés from Anaxomics take us through a few key approaches.
 
view
download pdf
Substance Repurposing

Lease of Life

Re-Pharm’s Robert Scoffin
and Alan Rothaul explain how combining pharmacological expertise and computational chemistry tools can help to identify new activity for existing compounds.


 
view
download pdf
Orthogonal Techniques

It’s a Small World


Regulatory authorities have voiced concern over the safety and efficacy of therapeutic protein products, calling for greater monitoring of subvisible particles. Amber Fradkin of KBI Biopharma outlines the different characterisation techniques firms can utilise to meet mounting requirements.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
In Brief

In the Lead


Industry advisor Emile Bellott examines the biosimilar market, noting the enthusiasm of European and Asian regulators, as well as commenting on what the future holds for the US.
 
view
download pdf
bullet
MARKETPLACE
Antibody Therapeutics

Hard to Resist


Pharmaceutical and biotechnology firms are increasingly developing antibody therapies to cash in on the success of drugs like Humira and Remicade. MRC Technology’s Michael Dalrymple muses on this growing sector.
 
view
download pdf
bullet
REGIONAL FOCUS: AFRICA
Industry Interview

Target Market


Speaking to EBR, PharmaAfrica’s Miles Mudzviti urges pharma to start considering the African market. With rising health investment and growing consumerism, the time is now to begin investing.
 
view
download pdf
Regional Focus

Out of Africa


A continent of largely untapped potential, Africa could provide the perfect opportunity for pharma companies looking to expand their global reach. EBR’s Emma Naks reports on the risks and rewards of expanding into this emerging region.
 
view
download pdf
bullet
CELL-BASED RESEARCH
Cancer Stem Cells

Stemming the Tide


Axis BioServices’ Jenny Worthington reflects on one of the hot topics in oncology – cancer stem cells. Although they make up just a small proportion of tumour mass, their resistance to current therapies demands further study into their behaviour.
 
view
download pdf
Anti-Cancer Drug Delivery

Hitting the Mark


Research into cell biology has uncovered new ways of targeting specific drugs to reach cancer cells – improving patient outcomes and reducing side-effects. Aidan Seeley and Heather M Wallace at the University of Aberdeen go into more detail.
 
view
download pdf
Stem Cell Research

Under Investigation


Regina Au at BioMarketing Insight comments on the recent breakthroughs in stem cell research and discusses their many applications across cancer therapeutics, drug development and transplantations.


 
view
download pdf
bullet
THERAPEUTIC DEVELOPMENT
Spotlight on Malaria

Biting Back


Responsible for over 500,000 deaths each year, malaria remains a force to be reckoned with. John Haselden of GlaxoSmithKline talks about the de novo combination treatments needed to eradicate the disease and prevent the emergence of resistance.
 
view
download pdf
Precision Medicine

Hand-in-Hand

Kenneth Butz and Holly Hilton of PPD reveal how novel trial designs – as well as the simultaneous introduction of targeted therapies and in vitro companion diagnostic devices – can hasten advances in precision medicine.
 
view
download pdf
Companion Diagnostics

Testing Patients


Autoimmune diseases – such as lupus – remain difficult to treat. Protagen’s Petra Budde and Peter Schulz-Knappe hope that pharma will respond by aligning companion diagnostic development with clinical programmes.
 
view
download pdf
Epigenetics

New Direction


Ewelina Kulikowski at Resverlogix Corp suggests that BET inhibition – which can impact upon many different biologies – could demonstrate potential as a novel, epigenetic approach to treating a variety of illnesses.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Progress Published in Screening for New Cancer Compounds in Context of Radiation Therapy

A recent publication by BMC Cancer discusses a comfortable 3D cell-based phenotypic assay enabling high throughput screening of compounds with radiation therapy modulating capacity, opening the field to drug discovery.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

Industry Events

BioProcess International (BPI) Conference & Exposition

26-29 October 2015, Hynes Convention Center, Boston, Massachusetts

BioProcess International (BPI) Conference & Exhibition is the world's largest gathering of bioprocessing and biomanufacturing scientists, executives and technology providers, bringing over 1,600 attendees, 150 exhibitors, 160 speakers and 100 posters to Boston.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement